Junior Meltus Chesty Coughs with Catarrh

Country: Malta

Bahasa: Inggeris

Sumber: Medicines Authority

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
26-05-2024
Ciri produk Ciri produk (SPC)
26-05-2024

Bahan aktif:

CETYLPYRIDINIUM CHLORIDE, GUAIFENESIN

Boleh didapati daripada:

Cupal Limited 103 - 105 Bath Road Slough, SL1 3UK, United Kingdom

Kod ATC:

R05DA09

INN (Nama Antarabangsa):

CETYLPYRIDINIUM CHLORIDE 2.5 mg GUAIFENESIN 50 mg

Borang farmaseutikal:

ORAL LIQUID

Komposisi:

CETYLPYRIDINIUM CHLORIDE 2.5 mg GUAIFENESIN 50 mg

Jenis preskripsi:

OTC

Kawasan terapeutik:

COUGH AND COLD PREPARATIONS

Status kebenaran:

Withdrawn

Tarikh kebenaran:

2007-07-12

Ciri produk

                                 
        Page 1 of 3 
 
SUMMARY OF PRODUCT CHARACTERISTICS 
 
 
1. 
NAME OF MEDICINAL PRODUCT 
 
Junior Meltus Chesty Coughs with Catarrh 
 
2. 
QUALITATIVE AND QUANTITATIVE COMPOSITION 
 
Guaiphenesin 50 mg 
Cetylpyridinium Chloride 2.5 mg 
 
3. PHARMACEUTICAL 
FORM 
 
Oral Liquid. 
 
4. CLINICAL 
PARTICULARS 
 
4.1 THERAPEUTIC 
INDICATIONS 
 
For the symptomatic relief of coughs and catarrh associated with
influenza, colds and mild 
throat infections. 
 
4.2  POSOLOGY AND METHOD OF ADMINISTRATION 
 
To be taken three to four times daily. 
_Children over 6 years_:  Two 5 ml spoonfuls 
_Children 1-6 years_: 
 
One 5 ml spoonful 
_Children under 1 year_:  Not recommended unless on medical
advice. 
 
4.3 CONTRAINDICATIONS 
 
This product is contraindicated in patients hypersensitive to any of
the ingredients. 
 
4.4  SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE 
 
Children under 1 year of age - this product should only be
administered with medical advice. 
 
4.5  INTERACTION WITH OTHER MEDICAMENTS AND OTHER FORMS
OF INTERACTION 
 
Can cause transient abnormality in platelet aggregation patterns
determined one hour after 
ingestion.  
 
4.6  PREGNANCY AND LACTATION 
 
Although there are no known contra-indications, as with
all medicines caution should be 
exercised when administering to pregnant or lactating women. 
 
4.7  EFFECTS ON ABILITY TO DRIVE AND TO USE MACHINES 
 
Mild drowsiness has been reported. 
 
 
        Page 2 of 3 
 
4.8 UNDESIRABLE 
EFFECTS 
 
Some gastro-intestinal discomfort and mild drowsiness has been
reported.  Very large doses 
can cause nausea and vomiting. 
 
4.9 OVERDOSE 
 
Very large doses may cause nausea and vomiting.  It is however,
rapidly metabolised and 
excreted in the urine.  The patient should be kept
under observation and treated 
symptomatically. 
 
5. PHARMACOLOGICAL 
PROPERTIES 
 
5.1 PHARMACODYNAMIC 
PROPERTIES 
 
A cou
                                
                                Baca dokumen lengkap